(PharmaNewsWire.Com, June 28, 2017 ) Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2) -like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease (American Trypanosomiasis) , Chronic Obstructive Pulmonary Disease (COPD) , Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis (Scleroderma) , Type 1 Diabetes (Juvenile Diabetes) , Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease (Chronic Renal Failure) , Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS) , Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis (RRMS) , Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.
The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.
- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects - The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Arbor Pharmaceuticals LLC Bayer AG BioApex sro Biogen Inc C4X Discovery Holdings PLC Catabasis Pharmaceuticals Inc Daiichi Sankyo Company Ltd Evgen Pharma Plc Ixchel Pharma LLC Jiangsu Hengrui Medicine Co Ltd Mochida Pharmaceutical Co Ltd Reata Pharmaceuticals Inc Rigel Pharmaceuticals Inc vTv Therapeutics Inc
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Arbor Pharmaceuticals LLC, H1 2017 Pipeline by Bayer AG, H1 2017 Pipeline by BioApex sro, H1 2017 Pipeline by Biogen Inc, H1 2017 Pipeline by C4X Discovery Holdings PLC, H1 2017 Pipeline by Catabasis Pharmaceuticals Inc, H1 2017 Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Pipeline by Evgen Pharma Plc, H1 2017 Pipeline by Ixchel Pharma LLC, H1 2017 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017 Pipeline by Reata Pharmaceuticals Inc, H1 2017 Pipeline by Rigel Pharmaceuticals Inc, H1 2017 Pipeline by vTv Therapeutics Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1) , H1 2017 Dormant Products, H1 2017 (Contd..2) , H1 2017 Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
